Clinical Trials & Research Studies in Canada(Updated 8/25)

A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies

NCT05123482

Recruiting

This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/13/2025

Locations: Research Site, Duarte, California +65 locations

Research Site, Duarte, California

Research Site, Irvine, California

Research Site, Santa Monica, California

Research Site, Santa Rosa, California

Research Site, Sarasota, Florida

Research Site, Shreveport, Louisiana

Research Site, Baltimore, Maryland

Research Site, Boston, Massachusetts

Research Site, Saint Louis, Missouri

Research Site, Albuquerque, New Mexico

Research Site, Commack, New York

Research Site, New York, New York

Research Site, Charlotte, North Carolina

Research Site, Pittsburgh, Pennsylvania

Research Site, Houston, Texas

Research Site, Clayton, Not set

Research Site, Melbourne, Not set

Research Site, Nedlands, Not set

Research Site, South Brisbane, Not set

Research Site, Anderlecht, Not set

Research Site, Leuven, Not set

Research Site, Calgary, Alberta

Research Site, Vancouver, British Columbia

Research Site, Ottawa, Ontario

Research Site, Toronto, Ontario

Research Site, Montreal, Quebec

Research Site, Beijing, Not set

Research Site, Changsha, Not set

Research Site, Chongqing, Not set

Research Site, Guangzhou, Not set

Research Site, Kunming, Not set

Research Site, Shandong, Not set

Research Site, Budapest, Not set

Research Site, Milan, Not set

Research Site, Modena, Not set

Research Site, Roma, Not set

Research Site, Rozzano, Not set

Research Site, Chuo-ku, Not set

Research Site, Hidaka-shi, Not set

Research Site, Kashiwa, Not set

Research Site, Koto-ku, Not set

Research Site, Kurume-shi, Not set

Research Site, Sunto-gun, Not set

Research Site, Seoul, Not set

Research Site, Amsterdam, Not set

Research Site, Gdańsk, Not set

Research Site, Warszawa, Not set

Research Site, Barcelona, Not set

Research Site, L'Hospitalet de Llobregat, Not set

Research Site, Madrid, Not set

Research Site, Málaga, Not set

Research Site, Pamplona, Not set

Research Site, Tainan, Not set

Research Site, Taipei, Not set

Research Site, Taoyuan, Not set

Research Site, Bangkok, Not set

Research Site, Chiang Mai, Not set

Research Site, Cambridge, Not set

Research Site, Cardiff, Not set

Research Site, London, Not set

Conditions: Breast Cancer, Ovarian Cancer, Endometrial Cancer, Biliary Tract Carcinoma, Squamous Non-Small Cell Lung Cancer

Register for Updates

Learn More ›

DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics

NCT02288676

Recruiting

This study aims to develop and validate a test for detecting ovarian and endometrial cancers early. It relies on detecting somatic mutations that are associated with these cancers from a uterine pap test. A saliva sample is also collected that acts as an internal control and has the ability to detect deleterious germline mutations associated with common hereditary cancers (such as breast, ovarian, endometrial, colon, and pancreatic cancers). A machine learning classifier is then used to discrimi... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/13/2025

Locations: Royal Victoria Hospital (Glen Site), Montreal, Quebec

Conditions: Ovarian Neoplasms, Endometrial Neoplasms, Endometrial Cancer, Ovarian Cancer, Screening, Safety, Reduced Mortality, Reduced Morbidity, Early Diagnosis

Register for Updates

Learn More ›

The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial

NCT05446272

Recruiting

DIVA is a pragmatic randomized clinical trial (RCT) to determine: among (P) preterm infants born 23 0/7-28 6/7 weeks gestation undergoing extubation from mechanical ventilation, whether (I) Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) (C) compared with Non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV), will reduce the incidence of (O) extubation failure within (T) 5 days (120 hours) of extubation.

Gender:

ALL

Ages:

Between 0 days and 9 weeks

Trial Updated:

06/13/2025

Locations: Arkansas Children's Hospital, Little Rock, Arkansas +19 locations

Conditions: Extubation Failure, Bronchopulmonary Dysplasia, Death

Register for Updates

Learn More ›

Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

NCT06998056

Recruiting

This study will assess the safety and tolerability of ARQ-151 cream 0.05% applied once a day for 4 weeks in infants with atopic dermatitis (eczema).

Gender:

ALL

Ages:

Between 3 months and 2 years

Trial Updated:

06/13/2025

Locations: Arcutis Clinical Study Site 208, Birmingham, Alabama +12 locations

Conditions: Atopic Dermatitis (Eczema)

Register for Updates

Learn More ›

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05995353

Recruiting

Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to \< 18 years old who have had intolerance or inadequate response to other therapies. Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is be... Read More

Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to \< 18 years old who have had intolerance or inadequate response to other therapies. Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is being developed for the treatment of CD in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1 will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based induction regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Around 110 pediatric participants with CD will be enrolled at around 100 sites worldwide. Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires. Read Less

Gender:

ALL

Ages:

Between 2 years and 17 years

Trial Updated:

06/13/2025

Locations: Phoenix Children's Hospital /ID# 255766, Phoenix, Arizona +82 locations

Phoenix Children's Hospital /ID# 255766, Phoenix, Arizona

Arkansas Children's Hospital /ID# 255762, Little Rock, Arkansas

UCSF Benioff Children's Hospital - Oakland /ID# 258327, Oakland, California

Children's Hospital Colorado - Aurora /ID# 255764, Aurora, Colorado

Arnold Palmer Hospital for Children Center Digestive Health & Nutrition - Orland /ID# 255437, Orlando, Florida

Indiana University Health Riley Hospital for Children /ID# 256454, Indianapolis, Indiana

Massachusetts General Hospital /ID# 255767, Boston, Massachusetts

MNGI Digestive Health, P. A. /ID# 255366, Minneapolis, Minnesota

Goryeb Children's Hospital /ID# 256452, Morristown, New Jersey

Icahn School of Medicine at Mount Sinai /ID# 254880, New York, New York

Cleveland Clinic - Cleveland /ID# 256453, Cleveland, Ohio

Uza /Id# 255114, Edegem, Antwerpen

Cliniques Universitaires UCL Saint-Luc /ID# 255108, Bruxelles, Bruxelles-Capitale

Universitair Ziekenhuis Brussel /ID# 255109, Jette, Bruxelles-Capitale

Universitair Ziekenhuis Leuven /ID# 255098, Leuven, Vlaams-Brabant

Hospital Universite Enfants Reine Fabiola /ID# 255112, Bruxelles, Not set

Groupe Sante CHC - Clinique du MontLegia /ID# 255620, Liege, Not set

UMHAT Sveti Georgi /ID# 255386, Plovdiv, Not set

Specialized Hospital For Active Treatment Of Children Diseases Prof. Ivan Mitev /ID# 255384, Sofiya, Not set

UMHAT Sveta Marina /ID# 256358, Varna, Not set

Alberta Children's Hospital /ID# 255357, Calgary, Alberta

BC Children's Hospital /ID# 255359, Vancouver, British Columbia

London Health Sciences Center- University Hospital /ID# 258598, London, Ontario

Beijing Children's Hospital /ID# 256081, Beijing, Beijing

Peking University Third Hospital /ID# 255876, Beijing, Beijing

Guangzhou Medical University Affiliated Women and Children's Medical Center /ID# 255428, Guangzhou, Guangdong

The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 270589, Guangzhou, Guangdong

Henan Children's Hospital Zhengzhou Children's Hospital /ID# 255562, Zhengzhou, Henan

Hunan Children's Hospital /ID# 255610, Changsha, Hunan

Jiangxi Provincial Children's Hospital /ID# 255564, Nanchang, Jiangxi

Shengjing Hospital of China Medical University /ID# 255563, Shenyang, Liaoning

Children's Hospital of Shanghai /ID# 255531, Shanghai, Shanghai

Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 255688, Shanghai, Shanghai

Fakultní nemocnice v Motole /ID# 256547, Prague, Praha 5

Vseobecna fakultni nemocnice v Praze /ID# 256096, Praha, Not set

CHRU Tours - Hopital Gatien de Clocheville /ID# 255052, Tours, Centre-Val De Loire

CHU Bordeaux - Hopital Pellegrin /ID# 257060, Bordeaux, Nouvelle-Aquitaine

Hospices Civils de Lyon - Hôpital Femme Mère Enfant /ID# 255443, Bron CEDEX, Rhone

AP-HP - Hopital Necker /ID# 255608, Paris, Not set

CHU Toulouse - Hopital Paule de Viguier /ID# 255609, Toulouse, Not set

Dr. von Haunerschen Kinderspital /ID# 255577, Muenchen, Bayern

Universitaetsklinikum Muenster /ID# 256762, Muenster, Nordrhein-Westfalen

Schneider Children's Medical Center /ID# 254950, Petah Tikva, HaMerkaz

Shaare Zedek Medical Center /ID# 254951, Jerusalem, Yerushalayim

IRCCS Istituto Giannina Gaslini /ID# 255262, Genoa, Genova

Azienda Ospedaliera Universitaria Federico II /ID# 255045, Naples, Napoli

Azienda Ospedaliera Universitaria Gaetano Martino /ID# 255044, Messina, Not set

Aichi Children'S Health And Medical Center /ID# 272085, Obu, Aichi

Tsujinaka Hospital Kashiwanoha /ID# 268409, Kashiwa-shi, Chiba

Kurume University Hospital /ID# 268418, Kurume-shi, Fukuoka

Gunma University Hospital /ID# 270560, Maebashi-shi, Gunma

Japanese Red Cross Kumamoto Hospital /ID# 268586, Kumamoto-shi, Kumamoto

Osaka Women's and Children's Hospital /ID# 268419, Izumi-Shi, Osaka

Saitama Children's Medical Center /ID# 268410, Saitama-shi, Saitama

Institute of Science Tokyo Hospital /ID# 269175, Bunkyo-ku, Tokyo

Tokyo Metropolitan Children's Medical Center /ID# 268415, Fuchu-shi, Tokyo

National Center for Child Health and Development /ID# 268420, Setagaya-ku, Tokyo

Seoul National University Hospital /ID# 255318, Seoul, Seoul Teugbyeolsi

Yonsei University Health System Severance Hospital /ID# 256976, Seoul, Seoul Teugbyeolsi

Samsung Medical Center /ID# 255284, Seoul, Seoul Teugbyeolsi

Kyungpook National University Chilgok Hospital /ID# 255817, Daegu, Not set

Amsterdam UMC, locatie AMC /ID# 254827, Amsterdam, Noord-Holland

Gastromed Sp. z o.o /ID# 255939, Torun, Kujawsko-pomorskie

Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 255938, Warszawa, Mazowieckie

Puerto Rico Health Institute /ID# 255071, Dorado, Not set

Clinical Research Puerto Rico /ID# 266479, San Juan, Not set

Hospital Arquitecto Marcide - Complejo Hospitalario Universitario de Ferrol /ID# 255614, Ferrol, A Coruna

Hospital Infantil Universitario Nino Jesus /ID# 255012, Madrid, Not set

Hospital Regional Universitario de Malaga /ID# 257553, Malaga, Not set

Karolinska University Hospital Solna /ID# 255240, Solna, Stockholms Lan

Sodersjukhuset /ID# 255239, Stockholm, Stockholms Lan

Sahlgrenska Universitetssjukhuset /ID# 255236, Göteborg, Vastra Gotalands Lan

Kinderspital Zurich - Eleonorenstiftung /ID# 255337, Zurich, Zuerich

Inselspital, Universitaetsspital Bern /ID# 255321, Bern, Not set

National Taiwan University Hospital /ID# 255679, Taipei City, Taipei

Changhua Christian Hospital /ID# 256082, Changhua City, Changhua County, Not set

Gazi University Medical Faculty /ID# 255086, Ankara, Not set

Sariyer Hamidiye Etfal Eğitim Ve Araştirma Hastanesi /ID# 257143, Istanbul, Not set

Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 261020, Istanbul, Not set

Kocaeli University Med Faculty /ID# 256922, Kocaeli, Not set

Sheffield Children's Hospital NHS Foundation Trust /ID# 255758, Sheffield, England

Disc_Barts Health NHS Trust - The Royal London Hospital /ID# 255757, London, Greater London

Birmingham Women's and Children's NHS Foundation Trust /ID# 255759, Birmingham, Not set

Conditions: Crohn's Disease

Register for Updates

Learn More ›

Enhancing Heat Resiliency in Older Adults During Indoor Overheating Via Heat Acclimation by Warm Water Immersion

NCT06670365

Recruiting

As overheating in buildings is expected to increase as global warming continues, proactive measures to increase heat resiliency in heat-vulnerable older people are needed, especially for those without access to home cooling or reliable sources of electricity. While short-term heat acclimation through exercise in the heat has been shown to increase heat dissipation and decrease both the physical and mental stress imposed on individuals exposed to heat, such protocols are not tenable for older, se... Read More

As overheating in buildings is expected to increase as global warming continues, proactive measures to increase heat resiliency in heat-vulnerable older people are needed, especially for those without access to home cooling or reliable sources of electricity. While short-term heat acclimation through exercise in the heat has been shown to increase heat dissipation and decrease both the physical and mental stress imposed on individuals exposed to heat, such protocols are not tenable for older, sedentary adults. A recent report showed that seven consecutive days of warm-water immersion improved whole-body heat loss and reduced physiological strain as assessed during an exercise-heat stress in habitually active older men This represents a critical finding as an increase heat-loss capacity would serve as an important safeguard for older adults exposed to indoor overheating due to lack of air-conditioning. While this preliminary data highlights passive hot water immersion as a promising strategy for increasing heat-resilience in vulnerable adults, work is needed to confirm its efficacy in more "real-world" environments. Thus, this study aims to assess the effectiveness of a 7-day passive heating (warm-water immersion with core temperature clamped at \~38.5°C for the final 60 minutes) protocol in mitigating increases in thermal and cardiovascular strain in older females exposed to daylong (10-hours) indoor overheating (36°C, 45% relative humidity) prior to and following the passive heating intervention. Relative to males, females have a reduced heat loss capacity (\~5%), which is driven by differences in the activation of heat loss responses (i.e., skin blood flow and sweating). Although there have been mixed findings with regards to the influence of sex as a mediating factor for heat-related mortality, some studies suggest that females are at a higher risk of heat-related mortality and morbidity compared to males, especially amongst older individuals (≥65 years). Notably, a greater proportion of older females died compared to their male counterparts during the 2021 Western Heat Dome. While the underlying causes for these differences remain unclear, greater cardiovascular strain may place females at higher mortality risk during extreme heat. Read Less

Gender:

FEMALE

Ages:

Between 65 years and 85 years

Trial Updated:

06/13/2025

Locations: University of Ottawa, Ottawa, Ontario

Conditions: Hyperthermia, Thermoregulation, Aging, Heat Acclimation and Thermotolerance

Register for Updates

Learn More ›

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

NCT04557462

Recruiting

The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who have completed either the CLNP023X2203 or CLNP023A2301 clinical trials. The open-label design of the current study is appropriate to provide study participants the opportunity to receive treatment with iptacopan until marketing authorizations are received and the drug product becomes commercially available while enabling collection of long-term safet... Read More

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

06/12/2025

Locations: AZ Kidney Dise and Hypertension Ctr, Glendale, Arizona +145 locations

AZ Kidney Dise and Hypertension Ctr, Glendale, Arizona

Kaiser Permanente, San Diego, California

North America Research Institute, San Dimas, California

University of Colorado Anschutz, Aurora, Colorado

Nephrology Associates PA, Newark, Delaware

CaRe Research, Chubbuck, Idaho

Nep Assoc of Northern Illinois, Hinsdale, Illinois

Johns Hopkins Hospital, Baltimore, Maryland

Brigham and Womens Hosp Harvard Med School, Boston, Massachusetts

Mayo Clinic Rochester, Rochester, Minnesota

Clinical Research Consultants LLC, Kansas City, Missouri

DaVita Clinical Research, Las Vegas, Nevada

New Jersey Kidney Care, Jersey City, New Jersey

Col Uni Med Center New York Presby, New York, New York

Prolato Clinical Research Center, Houston, Texas

Novartis Investigative Site, Caba, Buenos Aires

Novartis Investigative Site, Ciudad Autonoma de Buenos Aire, Not set

Novartis Investigative Site, Cordoba, Not set

Novartis Investigative Site, Santa Fe, Not set

Novartis Investigative Site, Woolloongabba, Queensland

Novartis Investigative Site, Adelaide, South Australia

Novartis Investigative Site, Parkville, Victoria

Novartis Investigative Site, Edegem, Not set

Novartis Investigative Site, Leuven, Not set

Novartis Investigative Site, Roeselare, Not set

Novartis Investigative Site, Belo Horizonte, MG

Novartis Investigative Site, Curitiba, PR

Novartis Investigative Site, Porto Alegre, RS

Novartis Investigative Site, Sao Paulo, SP

Novartis Investigative Site, Sao Jose do Rio Preto, Not set

Novartis Investigative Site, Oshawa, Ontario

Novartis Investigative Site, Beijing, Beijing

Novartis Investigative Site, Guangzhou, Guangdong

Novartis Investigative Site, Luoyang, Henan

Novartis Investigative Site, Changsha, Hunan

Novartis Investigative Site, Changchun, Jilin

Novartis Investigative Site, Yinchuan, Ningxia

Novartis Investigative Site, Taiyuan, Shanxi

Novartis Investigative Site, Urumqi, Xinjiang

Novartis Investigative Site, Wenzhou, Zhejiang

Novartis Investigative Site, Beijing, Not set

Novartis Investigative Site, Guang Zhou, Not set

Novartis Investigative Site, Qingdao, Not set

Novartis Investigative Site, Shanghai, Not set

Novartis Investigative Site, Shanxi, Not set

Novartis Investigative Site, Shenzhen, Not set

Novartis Investigative Site, Medellin, Antioquia

Novartis Investigative Site, Barranquilla, Not set

Novartis Investigative Site, Praha, Not set

Novartis Investigative Site, Aalborg, Not set

Novartis Investigative Site, Arhus N, Not set

Novartis Investigative Site, Copenhagen, Not set

Novartis Investigative Site, Odense C, Not set

Novartis Investigative Site, Marseille, Not set

Novartis Investigative Site, Montpellier 5, Not set

Novartis Investigative Site, Paris, Not set

Novartis Investigative Site, Aachen, Not set

Novartis Investigative Site, Berlin, Not set

Novartis Investigative Site, Essen, Not set

Novartis Investigative Site, Freiburg, Not set

Novartis Investigative Site, Hannover, Not set

Novartis Investigative Site, Heidelberg, Not set

Novartis Investigative Site, Magdeburg, Not set

Novartis Investigative Site, Mainz, Not set

Novartis Investigative Site, Stuttgart, Not set

Novartis Investigative Site, Tuebingen, Not set

Novartis Investigative Site, Ulm, Not set

Novartis Investigative Site, Pokfulam, Not set

Novartis Investigative Site, Debrecen, Not set

Novartis Investigative Site, New Delhi, Delhi

Novartis Investigative Site, Bangalore, Karnataka

Novartis Investigative Site, New Delhi, Not set

Novartis Investigative Site, Ashkelon, Not set

Novartis Investigative Site, Jerusalem, Not set

Novartis Investigative Site, Petach Tikva, Not set

Novartis Investigative Site, Bologna, BO

Novartis Investigative Site, Napoli, Not set

Novartis Investigative Site, Kasugai, Aichi

Novartis Investigative Site, Toyoake city, Aichi

Novartis Investigative Site, Toyota, Aichi

Novartis Investigative Site, Sapporo-city, Hokkaido

Novartis Investigative Site, Sapporo, Hokkaido

Novartis Investigative Site, Kawasaki, Kanagawa

Novartis Investigative Site, Yokohama-city, Kanagawa

Novartis Investigative Site, Yokohama, Kanagawa

Novartis Investigative Site, Sendai, Miyagi

Novartis Investigative Site, Matsumoto, Nagano

Novartis Investigative Site, Okayama-city, Okayama

Novartis Investigative Site, Omihachiman, Shiga

Novartis Investigative Site, Chiba, Not set

Novartis Investigative Site, Kyoto, Not set

Novartis Investigative Site, Niigata, Not set

Novartis Investigative Site, Osaka, Not set

Novartis Investigative Site, Cheongju si, Chungcheongbuk do

Novartis Investigative Site, Seoul, Korea

Novartis Investigative Site, Seoul, Seocho gu

Novartis Investigative Site, Busan, Not set

Novartis Investigative Site, Seoul, Not set

Novartis Investigative Site, Taegu, Not set

Novartis Investigative Site, Kuala Lumpur, Wilayah Persekutuan

Novartis Investigative Site, Kuala Lumpur, Not set

Novartis Investigative Site, Queretaro, Not set

Novartis Investigative Site, Groningen, Not set

Novartis Investigative Site, Nordbyhagen, Oslo

Novartis Investigative Site, Bergen, Not set

Novartis Investigative Site, Rostov On Don, Not set

Novartis Investigative Site, St Petersburg, Not set

Novartis Investigative Site, Singapore, Not set

Novartis Investigative Site, Kosice, Not set

Novartis Investigative Site, Ljubljana, Not set

Novartis Investigative Site, Maribor, Not set

Novartis Investigative Site, Salamanca, Castilla Y Leon

Novartis Investigative Site, Barcelona, Catalunya

Novartis Investigative Site, Pamplona, Navarra

Novartis Investigative Site, Stockholm, Not set

Novartis Investigative Site, Kaohsiung, Not set

Novartis Investigative Site, New Taipei City, Not set

Novartis Investigative Site, New Taipei, Not set

Novartis Investigative Site, Taichung, Not set

Novartis Investigative Site, Taipei, Not set

Novartis Investigative Site, Taoyuan, Not set

Novartis Investigative Site, Bangkok, Not set

Novartis Investigative Site, Istanbul, TUR

Novartis Investigative Site, Ankara, Not set

Novartis Investigative Site, Istanbul, Not set

Novartis Investigative Site, Kocaeli, Not set

Novartis Investigative Site, Mersin, Not set

Novartis Investigative Site, Talas Kayseri, Not set

Novartis Investigative Site, Cambridge, Not set

Novartis Investigative Site, Leicester, Not set

Novartis Investigative Site, London, Not set

Novartis Investigative Site, Newcastle upon Tyne, Not set

Novartis Investigative Site, Salford, Not set

Novartis Investigative Site, Ho Chi Minh, VNM

Conditions: Primary IgA Nephropathy

Register for Updates

Learn More ›

Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

NCT05822609

Recruiting

The primary objective of this study is to determine the effects of semaglutide on kidney oxygenation and function in type 1 diabetes. The secondary objective is to determine the glycemic effects and safety of semaglutide in type 1 diabetes.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/12/2025

Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +3 locations

Conditions: Diabetic Kidney Disease, Type 1 Diabetes

Register for Updates

Learn More ›

A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)

NCT05143177

Recruiting

This is an adaptive Phase 2/3 multicenter, double-blind, placebo-controlled, randomized, parallel, 2 arm study to evaluate the efficacy and safety of DA-1229 compared to placebo in patients with calcific aortic valve disease with mild to moderate aortic stenosis. There are 2 arms in this study to which patients will be randomized in a ratio of 1:1 to receive the DA-1229 or placebo orally once daily for a period of 104 weeks. The 2 arms are: placebo and DA-1229 10 mg Group. The study will have t... Read More

Gender:

ALL

Ages:

35 years and above

Trial Updated:

06/12/2025

Locations: Mayo Clinic, AZ, Phoenix, Arizona +24 locations

Conditions: Calcific Aortic Valve Disease

Register for Updates

Learn More ›

Implementing REmote SymPtom mOnitoring and maNagement (RESPONd)

NCT07024329

Recruiting

The goal of this study is to understand if the implementation of a remote symptom monitoring and management program improves outcomes. The program will provide patients the opportunity to complete electronic Patient Reported Outcomes (PROs) questionnaires from home between appointments and receive tailored advice from a study nurse. A second goal of this study is to examine the impact of electronic symptom monitoring on clinic efficiencies. The main question it aims to answer is: • What impact... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/12/2025

Locations: Arthur J. E. Child Comprehensive Cancer Centre, Calgary, Alberta +3 locations

Conditions: Cancer

Register for Updates

Learn More ›

NIRS in Congenital Heart Defects - Correlation With Echocardiography

NCT04106479

Recruiting

Neonatal patients with congenital heart defects (CHD) have changing physiology in the context of transitional period. Patients with CHD are at risk of low perfusion status or abnormal pulmonary blood flow. Near infrared spectroscopy has been used in neonatal intensive care units (NICU) to measure end-organ perfusion. The investigator plan on monitoring newborns with CHD admitted to the NICU with NIRS and echocardiography during the first week of life and correlate measures of perfusion from Dopp... Read More

Gender:

ALL

Ages:

Between 0 days and 7 days

Trial Updated:

06/12/2025

Locations: Mcgill University Health Centre, Montreal, Quebec

Conditions: Congenital Heart Defect, Single-ventricle, Coarctation of Aorta, Atrioventricular Canal, Hypoplastic Left Heart, Transposition of Great Vessels, Interrupted Aortic Arch, Tricuspid Atresia, Pulmonary Atresia, Aortic Atresia, Tetralogy of Fallot

Register for Updates

Learn More ›

Pulmonary Vascular Disease and Cardiac Performance in Extreme Preterm Infants

NCT04114435

Recruiting

Pulmonary vascular disease and cardiac performance in extreme preterm infants: A prospective cross-sectional study

Gender:

ALL

Ages:

Between 7 days and 5 years

Trial Updated:

06/12/2025

Locations: Mcgill University Health Centre, Montreal, Quebec

Conditions: Prematurity; Extreme

Register for Updates

Learn More ›

All Clinical Trials in Canada

Match to Clinical Trials